menu
    • menu

    Company profile for IsoTherapeutics Group

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    IsoTherapeutics Group, LLC (IsoTherapeutics) is a radiopharmaceutical company that was founded in 2005 by two entrepreneur scientists with a passion for advancing the technology of radiopharmaceuticals. The company scientists, while employed at the Dow Chemical Company, developed QUADRAMET® a radiopharmaceutical for treatment of bone pain due to metastatic cancer, treatments for arthritis, osteoporosis, and osteomyelitis, jus...
    IsoTherapeutics Group, LLC (IsoTherapeutics) is a radiopharmaceutical company that was founded in 2005 by two entrepreneur scientists with a passion for advancing the technology of radiopharmaceuticals. The company scientists, while employed at the Dow Chemical Company, developed QUADRAMET® a radiopharmaceutical for treatment of bone pain due to metastatic cancer, treatments for arthritis, osteoporosis, and osteomyelitis, just to name a few. IsoTherapeutics scientists have received over 100 patents for developing chemistry and radiopharmaceutical formulations.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    IsoTherapeutics GroupUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1004 S. Velasco St. Angleton, TX 77515
    Telephone
    Telephone
    (979) 848-0800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://isotherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Plus Expands Agreement with Telix for Rhenium-186 Supply
    Plus Expands Agreement with Telix for Rhenium-186 Supply

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990474/0/en/Plus-Therapeutics-Expands-Strategic-Agreement-with-Telix-IsoTherapeutics-Group-for-Rhenium-186-Radioisotope-Supply.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share
    Telix Reports Strong H1 2024 Revenue And Profit Growth
    Telix Reports Strong H1 2024 Revenue And Profit Growth

    22 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/22/2934023/0/en/Telix-2024-Half-Year-Results-Strong-Commercial-Revenue-and-Profit-Growth-to-Support-Strategic-Priorities.html

    GLOBENEWSWIRE
    22 Aug 2024
    Share Share
    Telix Pharma expands US infrastructure with acquisition of IsoTherapeutics
    Telix Pharma expands US infrastructure with acquisition of IsoTherapeutics

    27 Feb 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/23809/australian-firm-telix-pharma-expands-us-infrastructure-with-acquisition-of-isotherapeutics.html

    BIOSPECTRUM ASIA
    27 Feb 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Plus Expands Agreement with Telix for Rhenium-186 Radioisotope Supply

    Details:

    The agreement secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda, a novel injectable radiotherapy.


    Lead Product(s): 186-Re Obisbemeda,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Radiolabeled Compound

    Sponsor: Plus Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement December 03, 2024

    blank

    01

    IsoTherapeutics Group

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    IsoTherapeutics Group

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 186-Re Obisbemeda,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Plus Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Plus Expands Agreement with Telix for Rhenium-186 Radioisotope Supply

    Details : The agreement secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda, a novel injectable radiotherapy.

    Product Name : Undisclosed

    Product Type : Radiolabeled Compound

    Upfront Cash : Undisclosed

    December 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19

    Details:

    IsoTherapeutics will modify Monopar’s proprietary uPAR targeted antibody, MNPR-101, by making conjugates that will attachment of therapeutic radioisotopes supplied by NorthStar, creating a platform of uPAR-targeted RIT candidates to be studied to treat severe COVID-19.


    Lead Product(s): MNPR-101,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Antibody, Unconjugated

    Sponsor: NorthStar Medical Radioisotopes

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 10, 2020

    blank

    02

    IsoTherapeutics Group

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    IsoTherapeutics Group

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MNPR-101,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Discovery

    Partner/Sponsor/Collaborator : NorthStar Medical Radioisotopes

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic ...

    Details : IsoTherapeutics will modify Monopar’s proprietary uPAR targeted antibody, MNPR-101, by making conjugates that will attachment of therapeutic radioisotopes supplied by NorthStar, creating a platform of uPAR-targeted RIT candidates to be studied to treat...

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    August 10, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search